Literature DB >> 22086847

Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: long-term results of a prospective trial (National Clinical Trial 00254683).

Rodrigo Oliva Perez1, Angelita Habr-Gama, Joaquim Gama-Rodrigues, Igor Proscurshim, Guilherme Pagin São Julião, Patricio Lynn, Carla Rachel Ono, Fabio Guilherme Campos, Afonso Henrique Silva e Sousa, Antonio Rocco Imperiale, Sergio Carlos Nahas, Carlos Alberto Buchpiguel.   

Abstract

BACKGROUND: Neoadjuvant chemoradiation (CRT) therapy may result in significant tumor regression in patients with rectal cancer. Patients who develop complete tumor regression have been managed by treatment strategies that are alternatives to standard total mesorectal excision. Therefore, assessment of tumor response with positron emission tomography/computed tomography (PET/CT) after neoadjuvant treatment may offer relevant information for the selection of patients to receive alternative treatment strategies.
METHODS: Patients with clinical T2 (cT2) through cT4NxM0 rectal adenocarcinoma were included prospectively. Neoadjuvant therapy consisted of 54 grays of radiation and 5-fluorouracil-based chemotherapy. Baseline PET/CT studies were obtained before CRT followed by PET/CT studies at 6 weeks and 12 weeks after the completion of CRT. Clinical assessment was performed at 12 weeks after CRT completion. PET/CT results were compared with clinical and pathologic data.
RESULTS: In total, 99 patients were included in the study. Twenty-three patients were complete responders (16 had a complete clinical response, and 7 had a complete pathologic response). The PET/CT response evaluation at 12 weeks indicated that 18 patients had a complete response, and 81 patients had an incomplete response. There were 5 false-negative and 10 false-positive PET/CT results. PET/CT for the detection of residual cancer had 93% sensitivity, 53% specificity, a 73% negative predictive value, an 87% positive predictive value, and 85% accuracy. Clinical assessment alone resulted in an accuracy of 91%. PET/CT information may have detected misdiagnoses made by clinical assessment alone, improving overall accuracy to 96%.
CONCLUSIONS: Assessment of tumor response at 12 weeks after CRT completion with PET/CT imaging may provide a useful additional tool with good overall accuracy for the selection of patients who may avoid unnecessary radical resection after achieving a complete clinical response. Cancer 2012;3501-3511. © 2011 American Cancer Society.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 22086847     DOI: 10.1002/cncr.26644

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

1.  Clinical complete regression after local radiotherapy combined with chemotherapy for stage IV rectal cancer: A case report.

Authors:  Yazheng Dang; Hongxiang Gao; Shigao Huang; Tao Qi
Journal:  Mol Clin Oncol       Date:  2020-05-22

Review 2.  Local Excision and Endoscopic Resections for Early Rectal Cancer.

Authors:  Guilherme Pagin São Julião; Juan Pablo Celentano; Flavia Andrea Alexandre; Bruna Borba Vailati
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 3.  Management of the Complete Clinical Response.

Authors:  Angelita Habr-Gama; Guilherme Pagin São Julião; Bruna Borba Vailati; Ivana Castro; Debora Raffaele
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

4.  Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer.

Authors:  F Alongi; S Fersino; R Mazzola; A Fiorentino; N Giaj-Levra; F Ricchetti; R Ruggieri; G Di Paola; M Cirillo; S Gori; M Salgarello; G Zamboni; G Ruffo
Journal:  Clin Transl Oncol       Date:  2016-06-07       Impact factor: 3.405

5.  Neoadjuvant chemoradiotherapy of the rectal carcinoma - The correlation between the findings on the restaging multiparametric 3T MRI scanning and the surgical findings.

Authors:  Radovan Vojtíšek; Eva Korčáková; Jan Mařan; Ondřej Šorejs; Jindřich Fínek
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-05

6.  Management of distal rectal cancer: results from a national survey.

Authors:  G Melotti; E De Antoni; A Habr-Gama; A Minicozzi
Journal:  Updates Surg       Date:  2013-01-19

7.  Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging.

Authors:  R O Perez; A Habr-Gama; G P São Julião; P B Lynn; C Sabbagh; I Proscurshim; F G Campos; J Gama-Rodrigues; S C Nahas; C A Buchpiguel
Journal:  Tech Coloproctol       Date:  2014-02-08       Impact factor: 3.781

8.  Assessment of remaining tumour involved lymph nodes with MRI in patients with complete luminal response after neoadjuvant treatment of rectal cancer.

Authors:  Per Loftås; Margrét Sturludóttir; Olof Hallböök; Karin Almlöv; Gunnar Arbman; Lennart Blomqvist
Journal:  Br J Radiol       Date:  2018-05-10       Impact factor: 3.039

Review 9.  Surgeon perspectives on the use and effects of neoadjuvant chemoradiation in the treatment of rectal cancer: a comprehensive review of the literature.

Authors:  Sami A Chadi; Marianna Berho; Steven D Wexner
Journal:  Langenbecks Arch Surg       Date:  2015-08-07       Impact factor: 3.445

Review 10.  Multidisciplinary treatment of rectal cancer in 2014: where are we going?

Authors:  Andrea Vignali; Paola De Nardi
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.